Lucid Diagnostics Inc
LUCD
Company Profile
Business description
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Contact
360 Madison Avenue
25th Floor
New YorkNY10017
USAT: +1 917 813-1828
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
70
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,167.30 | 40.20 | 0.44% |
| CAC 40 | 8,358.76 | 3.33 | -0.04% |
| DAX 40 | 25,405.34 | 143.70 | 0.57% |
| Dow JONES (US) | 49,590.20 | 86.13 | 0.17% |
| FTSE 100 | 10,140.70 | 16.10 | 0.16% |
| HKSE | 26,846.35 | 237.87 | 0.89% |
| NASDAQ | 23,733.90 | 62.56 | 0.26% |
| Nikkei 225 | 53,568.06 | 1,628.17 | 3.13% |
| NZX 50 Index | 13,640.80 | 42.49 | -0.31% |
| S&P 500 | 6,977.27 | 10.99 | 0.16% |
| S&P/ASX 200 | 8,837.70 | 46.40 | 0.53% |
| SSE Composite Index | 4,163.84 | 1.44 | -0.03% |